Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) has been given a consensus rating of “Buy” by the nineteen research firms that are presently covering the firm, MarketBeat reports. Six equities research analysts have rated the stock with a hold recommendation and thirteen have given a buy recommendation to the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $164.00.

Several research analysts have issued reports on ALXN shares. Raymond James started coverage on shares of Alexion Pharmaceuticals in a research report on Wednesday. They set an “outperform” rating and a $161.00 price objective on the stock. BidaskClub raised shares of Alexion Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Friday, March 1st. Royal Bank of Canada reissued an “outperform” rating and set a $186.00 price objective (up from $165.00) on shares of Alexion Pharmaceuticals in a research report on Wednesday, March 27th. Cowen reissued a “buy” rating and set a $165.00 price objective on shares of Alexion Pharmaceuticals in a research report on Wednesday, March 13th. Finally, Guggenheim reissued a “neutral” rating and set a $135.00 price objective on shares of Alexion Pharmaceuticals in a research report on Thursday, March 21st.

In other news, CAO Daniel Bazarko sold 2,000 shares of Alexion Pharmaceuticals stock in a transaction dated Thursday, February 14th. The shares were sold at an average price of $126.00, for a total value of $252,000.00. Following the sale, the chief accounting officer now owns 5,020 shares of the company’s stock, valued at $632,520. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 4.08% of the stock is owned by insiders.

Several large investors have recently modified their holdings of ALXN. Dimensional Fund Advisors LP boosted its holdings in shares of Alexion Pharmaceuticals by 37.0% in the third quarter. Dimensional Fund Advisors LP now owns 539,784 shares of the biopharmaceutical company’s stock valued at $75,032,000 after acquiring an additional 145,649 shares in the last quarter. Brown Advisory Inc. boosted its holdings in shares of Alexion Pharmaceuticals by 17.5% in the third quarter. Brown Advisory Inc. now owns 23,799 shares of the biopharmaceutical company’s stock valued at $3,309,000 after acquiring an additional 3,538 shares in the last quarter. Standard Life Aberdeen plc lifted its stake in shares of Alexion Pharmaceuticals by 10.9% in the third quarter. Standard Life Aberdeen plc now owns 69,872 shares of the biopharmaceutical company’s stock valued at $9,712,000 after purchasing an additional 6,873 shares during the period. Renaissance Technologies LLC acquired a new stake in shares of Alexion Pharmaceuticals in the third quarter valued at about $9,439,000. Finally, Jefferies Group LLC lifted its stake in shares of Alexion Pharmaceuticals by 124.6% in the third quarter. Jefferies Group LLC now owns 1,607 shares of the biopharmaceutical company’s stock valued at $223,000 after purchasing an additional 8,138 shares during the period. 95.01% of the stock is currently owned by institutional investors and hedge funds.

NASDAQ:ALXN traded up $3.96 during midday trading on Friday, hitting $141.61. 40,435 shares of the company were exchanged, compared to its average volume of 1,597,558. Alexion Pharmaceuticals has a fifty-two week low of $92.56 and a fifty-two week high of $141.80. The company has a debt-to-equity ratio of 0.31, a current ratio of 2.88 and a quick ratio of 2.48. The firm has a market capitalization of $30.93 billion, a P/E ratio of 19.98, a P/E/G ratio of 1.08 and a beta of 1.55.

Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its quarterly earnings results on Monday, February 4th. The biopharmaceutical company reported $2.14 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.60 by $0.54. Alexion Pharmaceuticals had a net margin of 1.88% and a return on equity of 18.15%. The firm had revenue of $1.13 billion for the quarter, compared to analyst estimates of $1.06 billion. During the same period last year, the business earned $1.48 EPS. Alexion Pharmaceuticals’s revenue for the quarter was up 24.1% compared to the same quarter last year. On average, sell-side analysts anticipate that Alexion Pharmaceuticals will post 8.51 EPS for the current year.

About Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and Soliris (eculizumab), a monoclonal antibody for the treatment of PNH, atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis.

Featured Article: What is the Difference Between Common Shares and Convertible Shares?

Analyst Recommendations for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.